Zacks Investment Research cut shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a buy rating to a hold rating in a research report released on Wednesday morning.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Several other research analysts also recently commented on the company. Jefferies Group LLC decreased their price objective on NewLink Genetics Corporation from $26.00 to $25.00 and set a buy rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus lifted their price objective on NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a buy rating in a report on Friday, November 3rd. Cantor Fitzgerald restated a buy rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Thursday, November 2nd. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a report on Friday, October 13th. They set a buy rating and a $22.00 price target on the stock. Finally, ValuEngine downgraded NewLink Genetics Corporation from a sell rating to a strong sell rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. NewLink Genetics Corporation currently has a consensus rating of Buy and an average price target of $23.43.
NewLink Genetics Corporation (NASDAQ:NLNK) traded up $0.15 on Wednesday, hitting $9.02. The stock had a trading volume of 1,035,500 shares, compared to its average volume of 1,307,983. NewLink Genetics Corporation has a 1 year low of $5.90 and a 1 year high of $25.17.
In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction that occurred on Friday, October 6th. The shares were bought at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in NLNK. UBS Asset Management Americas Inc. bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $297,000. Parametric Portfolio Associates LLC bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $555,000. Prudential Financial Inc. bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $443,000. American International Group Inc. boosted its position in NewLink Genetics Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 880 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in NewLink Genetics Corporation by 3.0% during the 1st quarter. Teachers Advisors LLC now owns 207,854 shares of the biotechnology company’s stock valued at $5,009,000 after acquiring an additional 6,047 shares in the last quarter. Institutional investors own 55.30% of the company’s stock.
NewLink Genetics Corporation Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.